GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
CORAL GABLES, Fla., May 02, 2018 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release first quarter 2018 financial results after market close on Wednesday, May 9, 2018. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Thursday, May 10, 2018 to discuss the financial results and to provide a corporate update.
Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.catalystpharma.com and clicking on the webcast link on the Investors home page.
A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. Firdapse® (amifampridine phosphate) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.
Catalyst is also developing CPP-115 to treat refractory infantile spasms. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2017 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Investor Contact Brian Korb Solebury Trout (646) 378-2923 [email protected] Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
